Abstract: Postmortem brain studies of older drivers killed in car accidents indicate that many had Alzheimer disease (AD) neuropathologic changes. We examined whether AD biomarkers are related to driving performance among cognitively normal older adults. Individuals with normal cognition, aged 65 + years, and driving at least once per week, were recruited. Participants (N = 129) took part in clinical assessments, a driving test, and positron emission tomography imaging with Pittsburgh compound B (PIB) and/or cerebrospinal fluid (CSF) collection. General linear models tested whether the number of driving errors differed as a function of each of the biomarker variables (mean cortical binding potential for PIB, and CSF Ab 42 , tau, ptau 181 , tau/Ab 42 , ptau 181 / Ab 42 ). Higher ratios of CSF tau/Ab 42 , ptau 181 /Ab 42 , and PIB mean cortical binding potential, were associated with more driving errors (P < 0.05). Preclinical AD may have subtle cognitive and functional effects, which alone may go unnoticed. However, when combined, these changes may impact complex behaviors such as driving.
S
eventeen percent (36.8 million) of the licensed US drivers are aged 65 years and above, and the number of older adults in the United States is expected to double within the next 40 years. It is well known that people with symptomatic Alzheimer disease (AD) are at an increased risk for impaired driving and motor vehicle accidents; therefore, it is expected that the number of drivers with AD will rise dramatically. Moreover, driving skills decline with advancing age even among cognitively normal individuals. 1, 2 There is a long preclinical stage of AD, during which AD neuropathology is present without detectable cognitive or functional impairment. Preclinical AD may have subtle cognitive and functional effects, which could combine to impair complex behaviors such as driving. Consistent with this idea, postmortem studies of the brains of older drivers who were killed in car accidents found that many had underlying AD neuropathologic changes. 3 Cerebral cortical plaques and tangles are the signature lesions of AD. In vivo imaging of fibrillar amyloid plaques can be obtained using positron emission tomography (PET) with amyloid tracers such as Pittsburgh compound B (PIB). Cerebrospinal fluid (CSF) biomarkers are based on assays of proteins that are integral to the pathologic hallmarks of AD, including soluble levels of brain beta-amyloid (Ab 42 ); and tau and phosphorylated tau (ptau 181 ), the principal components of neurofibrillary tangles. We examined whether these biomarkers are related to driving performance among cognitively normal older adults.
METHODS

Design
Participants with normal cognition (Clinical Dementia Rating = 0), 4 aged 65 years and older, a valid driver's license, and who were driving at least once per week, were recruited for this study from the pool of individuals already participating in longitudinal studies at the Knight Alzheimer's Disease Research Center. Participants took part in clinical and psychometric assessments, a performancebased driving test, and completed PET-PIB and/or CSF collection. The study was approved by the Washington University Human Research Protection Office, and written informed consent was obtained from all participants.
Clinical Assessments
A Clinical Dementia Rating is derived by experienced clinicians who synthesize information obtained from interviews with the participant and separately with a collateral source who knows the participant well. The clinician's judgment about the presence of dementia is based on the principle of intraindividual change where the individual is considered as his or her own control. 4 The clinical assessment battery also includes the Mini-Mental State Examination. 5 
Measurement of AD Biomarkers
Imaging PET-PIB imaging was used to determine the brain amyloid burden. Detailed information on our PET-PIB methodology is available. 6 The Freesurfer image analysis suite (version 5.3) was used to obtain estimates of total brain volume and intracranial volume.
CSF Biomarkers
We measured CSF analytes (Ab 42 , tau, and ptau 181 ) using sensitive and quantitative enzyme-linked immunosorbant assays [INNOTEST, Fujirebio (formerly Innogenetics), Ghent, Belgium]. CSF levels of Ab 42 have consistently been reported to be reduced in AD, whereas levels of tau and ptau 181 (and the ratios of tau/Ab 42 and ptau 181 /Ab 42 ) were elevated. 7 CSF was obtained by neurologists by standard lumbar puncture using a 22-G Sprotte spinal needle to draw 20 to 30 mL of CSF at 8:00 AM following an overnight fast. CSF samples were gently inverted and centrifuged at low speed to avoid possible gradient effects and frozen at À 841C after aliquoting into polypropylene tubes. All biomarker assays included a common reference standard, within-plate sample randomization, and strict standardized protocol adherence. Samples were reanalyzed if coefficients of variability exceeded 25% or if the pooled common CSF sample yielded widely discrepant values.
APOE Genotyping
Briefly, all DNA samples underwent stringent quality control before genotyping with the Illumina 610 or the Omniexpress chip. 8 Detailed information on APOE genotyping has been published. 8 
Driving Test
The 12-mile, modified Washington University Road Test, takes about an hour to complete and the Record of Driving Errors 9 was used to obtain the total number of driving errors made during the test. The course begins in a closed parking lot so that the participant becomes familiar with the study car, a 4-door sedan, and then proceeds to a community in-traffic route, which includes unprotected left hand turns, in addition to complex intersections and merges. 9 Following directions delivered by an occupational therapy/driving rehabilitation specialist sitting in the front seat, the participant drives through the entire modified Washington University Road Test route. The front seat occupational therapy/driving rehabilitation specialist can take control of the wheel if needed, and can apply a second, passenger-side brake if necessary.
Statistical Analyses
General linear models (adjusted for age, education, sex, race, APOE4, and error rater) were used to test whether the number of driving errors differed as a function of each of the biomarker variables (MCBP for PIB, and CSF Ab 42 , tau, ptau 181 , tau/Ab 42 , and ptau 181 /Ab 42 ). Because of concerns with variability among CSF assay performance and no consensus on specific biomarker levels that characterize AD, we did not use a predetermined cutoff value for dichotomization. Rather, we examined the frequency distributions of each biomarker variable, and divided each distribution into tertiles. Lower values of Ab 42 , and higher values of all other biomarkers studied here, are associated with preclinical AD. In the statistical analyses, therefore, we compared the lowest tertile for Ab 42 , and highest tertile for the other biomarker variables, to the remaining tertiles combined. We also used an adjusted general linear model to examine whether a psychometric composite score that comprised results from 10 psychometric tests 10 was associated with the number of driving errors. The composite score was dichotomized such that scores in the highest tertile were considered "better performance" compared with the remaining scores.
RESULTS
Individuals aged 64.9 to 88.2 years (N = 129) met the inclusion criteria and had processed amyloid brain imaging (N = 113) and/or CSF biomarker (N = 123) data available for analyses (Table 1 ). Higher ratios of CSF tau/Ab 42 and ptau 181 /Ab 42 , in addition to PIB MCBP, were associated with increased numbers of driving errors (Table 2 ). Lower levels of CSF Ab 42 were also associated with increases in the number of driving errors, but this did not reach statistical significance (P = 0.06). The psychometric composite score was also not associated with the number of driving errors (P = 0.68).
DISCUSSION
AD biomarker patterns consistent with the presence of underlying AD pathology were associated with an increased number of errors on a road test among cognitively normal older adults, indicating that in addition to cognitive outcomes, AD biomarkers can predict functional outcomes.
However, a composite score reflecting psychometric functioning was unassociated with the number of driving errors. Together, these results suggest that preclinical AD may have subtle cognitive and functional effects, which alone may go unnoticed. However, when combined, these cognitive and functional changes may impact complex behaviors such as driving.
As with the prediction of cognitive outcomes, 7 we found that CSF biomarkers that combine elements of amyloid and tau are better predictors of on-road driving behavior than biomarkers reflecting either component alone.
Because new diagnostic guidelines advocate the use of biomarkers to help identify both mild cognitive impairment due to AD and AD dementia, and are under investigation for clinical use to identify preclinical AD, biomarkers may soon be used routinely in the clinical setting to make diagnostic decisions. Moreover, multiple clinical trials are now underway to evaluate new drugs designed to prevent, stop, or slow the AD pathologic process. Current AD therapies administered during the symptomatic stage may only slightly improve clinical symptoms and their progression, leading researchers to conclude that interventions must start earlier in the pathologic process, among individuals who are still asymptomatic. Consequently, identifying sensitive tools to measure cognitive and functional changes in the early stages is an urgent priority. Although some have cautioned that it may not be feasible to assess functional impairment at the earliest stages of the disease, the present results suggest that on-the-road driving tests, or driving simulation, may eventually provide such a measure.
Our study has limitations. We used a 1-hour road test to assess driving performance, which may be an inadequate time to capture significant driving errors. In addition, a driving simulation test might provide more detailed information on the types and importance of driving errors and could be repeated in other settings and with other samples. Moreover, it is unclear whether the extent to which road tests reflect day-to-day driving in the participant's own environment. Future research should examine associations between AD biomarker levels among cognitively normal participants and day-to-day driving in the participant's own environment.
Despite these limitations, our results suggest that even among cognitively normal individuals, abnormal levels of AD biomarkers can be used to predict performance in driving, a task which involves multiple complex functional and cognitive processes. 
